TCM
PCRX icon

Timpani Capital Management’s Pacira BioSciences PCRX Stock Holding History

Timpani Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-55,210
Closed -$2.38M – 106
2018
Q4 		$2.38M Buy
+55,210
New +$2.58M 1.33% 29
2017
Q3 		– Sell
-72,654
Closed -$3.47M – 114
2017
Q2 		$3.47M Buy
+72,654
New +$3.37M 1.29% 35

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Timpani Capital Management's PCRX Position: Q1 2019 in Review

Timpani Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 55,210 shares — an estimated $2.38M sold.

Timpani Capital Management first reported a position in PCRX in Q2 2017 and held it in 2 quarters. The position peaked at $3.47M in Q2 2017. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • Timpani Capital Management reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
  • Timpani Capital Management sold 55,210 Pacira BioSciences shares in Q1 2019, an estimated $2.38M.
  • Timpani Capital Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 2 quarters.
  • Timpani Capital Management's Pacira BioSciences position peaked at $3.47M in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on Timpani Capital Management's 13F filing for Q1 2019, filed 10 May 2019.